Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + eltrombopag
- Development stage
- Unknown
- Lead developer
- Yunfeng Cheng
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
hydroxychloroquine + eltrombopag is a combination therapy being investigated for the treatment of antinuclear antibody (ANA)-positive primary immune thrombocytopenia (ITP). Hydroxychloroquine is a small molecule 4-aminoquinoline with immunomodulatory properties, traditionally used as an antimalarial and for autoimmune conditions like systemic lupus erythematosus; it works by inhibiting toll-like receptors (TLR7/9) and modulating lysosomal pH to interfere with antigen presentation. Eltrombopag is an orally active, small molecule thrombopoietin receptor (TPO-R) agonist that interacts with the transmembrane domain of the receptor to initiate signaling pathways that increase megakaryocyte proliferation and platelet production. This specific combination, studied by Yunfeng Cheng at Zhongshan Hospital, aims to leverage the immune-modulating effects of hydroxychloroquine to enhance the platelet-stimulating efficacy of eltrombopag in ITP patients with underlying autoimmunity indicated by ANA positivity.
- Other names
- HCQ + TPO-RAHydroxychloroquine plus Eltrombopag
02
Targets
TLR9 (Toll-like receptor 9)TPOR (Thrombopoietin receptor)BAX (Apoptosis regulator BAX)TFEB (Transcription factor EB)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on hydroxychloroquine + eltrombopag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + eltrombopag.